{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T17:06:36Z","timestamp":1792688796834,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T00:00:00Z","timestamp":1754697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T00:00:00Z","timestamp":1754697600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K09036"],"award-info":[{"award-number":["23K09036"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012910","name":"National Defense Medical College","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012910","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To investigate the efficacy and safety of 2% ganciclovir (GCV) eye drops for the treatment of primary cytomegalovirus anterior uveitis (CMV-AU)<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study design<\/jats:title>\n                    <jats:p>Retrospective cohort study<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study included 12 patients diagnosed with CMV-AU who were treated with 2% GCV eye drops. The patients\u2019 demographics, clinical presentations, treatment regimens, and outcomes were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The cohort consisted predominantly of men (11:1 ratio), with a mean age of 63.4 years and all presenting with unilateral disease. Common presenting symptoms were blurred vision and elevated intraocular pressure (IOP). After the initiation of 2% GCV eye drops, all the patients demonstrated positive responses, with improvement in BCVA, decreased IOP, and resolution of keratic precipitates including coin-shaped lesions. Recurrence of uveitis occurred in 66.7% of the patients and was managed with intensified topical corticosteroids, antiglaucoma medications, and\/or short-term oral GCV. IOP significantly decreased after treatment (\n                      <jats:italic>P<\/jats:italic>\n                      &lt;.05), whilst BCVA and corneal endothelial cell counts remained stable. No patients developed bullous keratopathy or required intravenous GCV. One patient underwent trabeculectomy for uncontrolled IOP.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study\u2019s findings suggest that 2% GCV eye drops are a safe and effective treatment option for primary CMV-AU, offering improvements in IOP and uveitis control. All the patients completed the treatment without serious adverse events, supporting the favorable safety profile of 2% GCV eye drops.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10384-025-01250-y","type":"journal-article","created":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T06:05:14Z","timestamp":1754719514000},"page":"973-981","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of 2% ganciclovir eye drops in the treatment of cytomegalovirus anterior uveitis"],"prefix":"10.1007","volume":"69","author":[{"given":"Yu","family":"Yoneda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Takenaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanae","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Yoneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyosuke","family":"Seki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Oyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Imazeki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4913-7089","authenticated-orcid":false,"given":"Masaru","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,9]]},"reference":[{"key":"1250_CR1","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/S0161-6420(02)00961-2","volume":"109","author":"NN Markomichelakis","year":"2002","unstructured":"Markomichelakis NN, Canakis C, Zafirakis P, Marakis T, Mallias I, Theodossiadis G. Cytomegalovirus as a cause of anterior uveitis with sectoral iris atrophy. Ophthalmology. 2002;109:879\u201382.","journal-title":"Ophthalmology"},{"key":"1250_CR2","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s00417-010-1510-y","volume":"249","author":"YS Hwang","year":"2011","unstructured":"Hwang YS, Shen CR, Chang SH, Lai CC, Liu CL, Chen KJ, et al. The validity of clinical feature profiles for cytomegaloviral anterior segment infection. Graefes Arch Clin Exp Ophthalmol. 2011;249:103\u201310.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1250_CR3","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.ajo.2008.09.001","volume":"146","author":"SP Chee","year":"2008","unstructured":"Chee SP, Jap A. Presumed Fuchs heterochromic iridocyclitis and Posner-Schlossman syndrome: comparison of cytomegalovirus-positive and negative eyes. Am J Ophthalmol. 2008;146:883-9.e1.","journal-title":"Am J Ophthalmol"},{"key":"1250_CR4","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1001\/archopht.118.8.1030","volume":"118","author":"Herpetic Eye Disease Study Group","year":"2000","unstructured":"Herpetic Eye Disease Study Group. Oral acyclovir for herpes simplex virus eye disease: effect on prevention of epithelial keratitis and stromal keratitis. Arch Ophthalmol. 2000;118:1030\u20136.","journal-title":"Arch Ophthalmol"},{"key":"1250_CR5","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1080\/09273948.2017.1394471","volume":"26","author":"NS Chan","year":"2018","unstructured":"Chan NS, Chee SP, Caspers L, Bodaghi B. Clinical features of CMV-associated anterior uveitis. Ocul Immunol Inflamm. 2018;26:107\u201315.","journal-title":"Ocul Immunol Inflamm"},{"key":"1250_CR6","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.survophthal.2021.12.006","volume":"67","author":"NR La Distia","year":"2022","unstructured":"La Distia NR, Putera I, Mayasari YD, Hikmahwati W, Pertiwi AM, Ridwan AS, et al. Clinical characteristics and treatment outcomes of cytomegalovirus anterior uveitis and endotheliitis: a systematic review and meta-analysis. Surv Ophthalmol. 2022;67:1014\u201330.","journal-title":"Surv Ophthalmol"},{"key":"1250_CR7","doi-asserted-by":"publisher","first-page":"378","DOI":"10.3109\/09273948.2014.950384","volume":"23","author":"JH Woo","year":"2015","unstructured":"Woo JH, Lim WK, Ho SL, Teoh SC. Characteristics of cytomegalovirus uveitis in immunocompetent patients. Ocul Immunol Inflamm. 2015;23:378\u201383.","journal-title":"Ocul Immunol Inflamm"},{"key":"1250_CR8","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S0002-9394(14)72610-8","volume":"120","author":"JD McCann","year":"1995","unstructured":"McCann JD, Margolis TP, Wong MG, Kuppermann BD, Luckie AP, Schwartz DM, et al. A sensitive and specific polymerase chain reaction-based assay for the diagnosis of cytomegalovirus retinitis. Am J Ophthalmol. 1995;120:219\u201326.","journal-title":"Am J Ophthalmol"},{"key":"1250_CR9","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/eye.2011.363","volume":"26","author":"N Kongyai","year":"2012","unstructured":"Kongyai N, Sirirungsi W, Pathanapitoon K, Tananuvat N, Kunavisarut P, Leechanachai P, et al. Viral causes of unexplained anterior uveitis in Thailand. Eye (Lond). 2012;26:529\u201334.","journal-title":"Eye (Lond)"},{"key":"1250_CR10","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.ajo.2007.12.015","volume":"145","author":"SP Chee","year":"2008","unstructured":"Chee SP, Bacsal K, Jap A, Se-Thoe SY, Cheng CL, Tan BH. Clinical features of cytomegalovirus anterior uveitis in immunocompetent patients. Am J Ophthalmol. 2008;145:834\u201340.","journal-title":"Am J Ophthalmol"},{"key":"1250_CR11","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.ophtha.2006.07.057","volume":"114","author":"SP Chee","year":"2007","unstructured":"Chee SP, Bacsal K, Jap A, Se-Thoe SY, Cheng CL, Tan BH. Corneal endotheliitis associated with evidence of cytomegalovirus infection. Ophthalmology. 2007;114:798\u2013803.","journal-title":"Ophthalmology"},{"key":"1250_CR12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.sjopt.2011.10.001","volume":"27","author":"A Alfawaz","year":"2013","unstructured":"Alfawaz A. Cytomegalovirus-related corneal endotheliitis: a review article. Saudi J Ophthalmol. 2013;27:47\u20139.","journal-title":"Saudi J Ophthalmol."},{"key":"1250_CR13","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.ophtha.2007.04.053","volume":"115","author":"N Koizumi","year":"2008","unstructured":"Koizumi N, Suzuki T, Uno T, Chihara H, Shiraishi A, Hara Y, et al. Cytomegalovirus as an etiologic factor in corneal endotheliitis. Ophthalmology. 2008;115:292-7.e3.","journal-title":"Ophthalmology"},{"key":"1250_CR14","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.ajo.2013.03.020","volume":"156","author":"M Ang","year":"2013","unstructured":"Ang M, Sng CC, Chee SP, Tan DT, Mehta JS. Outcomes of corneal transplantation for irreversible corneal decompensation secondary to corneal endotheliitis in Asian eyes. Am J Ophthalmol. 2013;156:260-6.e2.","journal-title":"Am J Ophthalmol"},{"key":"1250_CR15","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1097\/ICO.0b013e3181c325e2","volume":"29","author":"H Sonoyama","year":"2010","unstructured":"Sonoyama H, Araki-Sasaki K, Osakabe Y, Nakamura M, Amano S, Koizumi N, et al. Detection of cytomegalovirus DNA from cytomegalovirus corneal endotheliitis after penetrating keratoplasty. Cornea. 2010;29:683\u20135.","journal-title":"Cornea"},{"key":"1250_CR16","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.ophtha.2008.10.031","volume":"116","author":"A Anshu","year":"2009","unstructured":"Anshu A, Chee SP, Mehta JS, Tan DT. Cytomegalovirus endotheliitis in Descemet\u2019s stripping endothelial keratoplasty. Ophthalmology. 2009;116:624\u201330.","journal-title":"Ophthalmology"},{"key":"1250_CR17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ajo.2017.02.026","volume":"178","author":"M Abou Shousha","year":"2017","unstructured":"Abou Shousha M, Yoo SH, Sayed MS, Edelstein S, Council M, Shah RS, et al. In vivo characteristics of corneal endothelium\/Descemet membrane complex for the diagnosis of corneal graft rejection. Am J Ophthalmol. 2017;178:27\u201337.","journal-title":"Am J Ophthalmol"},{"key":"1250_CR18","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1097\/ICO.0000000000001797","volume":"38","author":"A Basilious","year":"2019","unstructured":"Basilious A, Chew HF. Topical ganciclovir for prophylaxis of cytomegalovirus endotheliitis in endothelial keratoplasty. Cornea. 2019;38:120\u20132.","journal-title":"Cornea"},{"key":"1250_CR19","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1007\/s00417-014-2782-4","volume":"252","author":"M Accorinti","year":"2014","unstructured":"Accorinti M, Gilardi M, Pirraglia MP, Amorelli GM, Nardella C, Abicca I, et al. Cytomegalovirus anterior uveitis: long-term follow-up of immunocompetent patients. Graefes Arch Clin Exp Ophthalmol. 2014;252:1817\u201324.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1250_CR20","doi-asserted-by":"publisher","first-page":"43349","DOI":"10.1038\/srep43349","volume":"7","author":"JA Choi","year":"2017","unstructured":"Choi JA, Kim JE, Noh SJ, Kyoung Kim E, Park CK, Paik SY. Enhanced cytomegalovirus infection in human trabecular meshwork cells and its implication in glaucoma pathogenesis. Sci Rep. 2017;7:43349.","journal-title":"Sci Rep"},{"key":"1250_CR21","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1186\/s12886-018-0917-9","volume":"18","author":"L Xi","year":"2018","unstructured":"Xi L, Zhang L, Fei W. Cytomegalovirus-related uncontrolled glaucoma in an immunocompetent patient: a case report and systematic review. BMC Ophthalmol. 2018;18:259.","journal-title":"BMC Ophthalmol"},{"key":"1250_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0191850","volume":"13","author":"S Waduthantri","year":"2018","unstructured":"Waduthantri S, Zhou L, Chee SP. Intra-cameral level of ganciclovir gel, 0.15% following topical application for cytomegalovirus anterior segment infection: a pilot study. PLoS ONE. 2018;13: e0191850.","journal-title":"PLoS ONE"},{"key":"1250_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-033175","volume":"9","author":"JS Takhar","year":"2019","unstructured":"Takhar JS, Joye AS, Somkijrungroj T, Laovirojjanakul W, Lin CP, Lietman TM, et al. A double masked randomised 4-week, placebo-controlled study in the USA, Thailand and Taiwan to compare the efficacy of oral valganciclovir and topical 2% ganciclovir in the treatment of cytomegalovirus anterior uveitis: study protocol. BMJ Open. 2019;9: e033175.","journal-title":"BMJ Open"},{"key":"1250_CR24","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1016\/j.ophtha.2012.07.024","volume":"119","author":"D Pavan-Langston","year":"2012","unstructured":"Pavan-Langston D, Welch CL, Zegans ME. Ganciclovir gel for cytomegalovirus keratouveitis. Ophthalmology. 2012;119:2411.","journal-title":"Ophthalmology"},{"key":"1250_CR25","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1089\/jop.2016.0138","volume":"33","author":"J Antoun","year":"2017","unstructured":"Antoun J, Willermain F, Makhoul D, Motulsky E, Caspers L, Relvas LJ. Topical ganciclovir in cytomegalovirus anterior uveitis. J Ocul Pharmacol Ther. 2017;33:313\u20138.","journal-title":"J Ocul Pharmacol Ther"},{"key":"1250_CR26","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1016\/S0161-6420(99)90342-1","volume":"106","author":"S Grover","year":"1999","unstructured":"Grover S, Fishman GA, Anderson RJ, Tozatti MS, Heckenlively JR, Weleber RG, et al. Visual acuity impairment in patients with retinitis pigmentosa at age 45 years or older. Ophthalmology. 1999;106:1780\u20135.","journal-title":"Ophthalmology"},{"key":"1250_CR27","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.ajo.2018.07.021","volume":"194","author":"S Touhami","year":"2018","unstructured":"Touhami S, Qu L, Angi M, Bojanova M, Touitou V, Lehoang P, et al. Cytomegalovirus anterior uveitis: clinical characteristics and long-term outcomes in a French series. Am J Ophthalmol. 2018;194:134\u201342.","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"1250_CR28","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3390\/v15010185","volume":"15","author":"J Zhang","year":"2023","unstructured":"Zhang J, Kamoi K, Zong Y, Yang M, Ohno-Matsui K. Cytomegalovirus anterior uveitis: clinical manifestations, diagnosis, treatment, and immunological mechanisms. Viruses. 2023;15(1):185.","journal-title":"Viruses"},{"key":"1250_CR29","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ajo.2021.03.060","volume":"228","author":"The Standardization of Uveitis Nomenclature (SUN) Working Group","year":"2021","unstructured":"The Standardization of Uveitis Nomenclature (SUN) Working Group. Classification criteria for cytomegalovirus anterior uveitis. Am J Ophthalmol. 2021;228:89\u201395.","journal-title":"Am J Ophthalmol"},{"issue":"19","key":"1250_CR30","doi-asserted-by":"publisher","first-page":"5811","DOI":"10.3390\/jcm11195811","volume":"11","author":"YW Kuo","year":"2022","unstructured":"Kuo YW, Chang EC, Lee CY, Lee SH, Liang IC, Chen YC, et al. Effectiveness of topical ganciclovir 2% monotherapy versus combined steroid therapy in cytomegalovirus endotheliitis. J Clin Med. 2022;11(19):5811.","journal-title":"J Clin Med"},{"key":"1250_CR31","doi-asserted-by":"publisher","first-page":"497","DOI":"10.3109\/09273948.2016.1142572","volume":"25","author":"A De-la-Torre","year":"2017","unstructured":"De-la-Torre A, Valdes-Camacho J, Foster CS. Bilateral herpes simplex uveitis: review of the literature and own reports. Ocul Immunol Inflamm. 2017;25:497\u2013502.","journal-title":"Ocul Immunol Inflamm"},{"key":"1250_CR32","doi-asserted-by":"publisher","first-page":"6687929","DOI":"10.1155\/2021\/6687929","volume":"2021","author":"Q Sheng","year":"2021","unstructured":"Sheng Q, Zhai R, Fan X, Kong X. The analysis of dynamic changes and prognosis of Posner-Schlossman syndrome with cytomegalovirus infection and antiviral therapy. J Ophthalmol. 2021;2021:6687929.","journal-title":"J Ophthalmol"},{"key":"1250_CR33","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1007\/s10792-020-01412-6","volume":"40","author":"A Yoshimura","year":"2020","unstructured":"Yoshimura A, Araki-Sasaki K, Toyokawa N, Fujiwara R, Jho N, Gomi F. Relationships between the clinical characteristics and copy numbers of DNA of cytomegalovirus determined by real-time PCR. Int Ophthalmol. 2020;40:2297\u2013305.","journal-title":"Int Ophthalmol"},{"key":"1250_CR34","doi-asserted-by":"publisher","first-page":"3395","DOI":"10.2147\/IDR.S370905","volume":"15","author":"PJ Chen","year":"2022","unstructured":"Chen PJ, Lin IH, Chi YC, Lai CC, Hung JH, Tseng SH, et al. Long-term outcome of treatment with 2% topical ganciclovir solution in cytomegalovirus anterior uveitis and corneal endotheliitis. Infect Drug Resist. 2022;15:3395\u2013403.","journal-title":"Infect Drug Resist."},{"key":"1250_CR35","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2016-000061","volume":"2","author":"N Keorochana","year":"2017","unstructured":"Keorochana N, Choontanom R. Efficacy and safety of an extemporaneous preparation of 2% ganciclovir eye drops in CMV anterior uveitis. BMJ Open Ophthalmol. 2017;2: e000061.","journal-title":"BMJ Open Ophthalmol."},{"key":"1250_CR36","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.ajo.2014.08.007","volume":"158","author":"CC Su","year":"2014","unstructured":"Su CC, Hu FR, Wang TH, Huang JY, Yeh PT, Lin CP, et al. Clinical outcomes in cytomegalovirus-positive Posner-Schlossman syndrome patients treated with topical ganciclovir therapy. Am J Ophthalmol. 2014;158:1024-31.e2.","journal-title":"Am J Ophthalmol"},{"key":"1250_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.848820","volume":"9","author":"Q Sheng","year":"2022","unstructured":"Sheng Q, Zhai R, Fan X, Kong X. 2% ganciclovir eye drops control Posner-Schlossman syndrome relapses with\/without cytomegalovirus intraocular reactivation. Front Med (Lausanne). 2022;9: 848820.","journal-title":"Front Med (Lausanne)."},{"key":"1250_CR38","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1080\/08820530802111010","volume":"23","author":"T Suzuki","year":"2008","unstructured":"Suzuki T, Ohashi Y. Corneal endotheliitis. Semin Ophthalmol. 2008;23:235\u201340.","journal-title":"Semin Ophthalmol."},{"key":"1250_CR39","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.2147\/OPTH.S376039","volume":"16","author":"K Mori","year":"2022","unstructured":"Mori K, Ye Y, Yokogawa H, Nishino T, Kobayashi A, Mori N, et al. Clinical features of glaucoma associated with cytomegalovirus corneal endotheliitis. Clin Ophthalmol. 2022;16:2705\u201311.","journal-title":"Clin Ophthalmol"},{"key":"1250_CR40","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1136\/bjo.2009.167767","volume":"94","author":"SP Chee","year":"2010","unstructured":"Chee SP, Jap A. Cytomegalovirus anterior uveitis: outcome of treatment. Br J Ophthalmol. 2010;94:1648\u201352.","journal-title":"Br J Ophthalmol"},{"key":"1250_CR41","doi-asserted-by":"publisher","first-page":"15210","DOI":"10.1038\/s41598-024-66224-5","volume":"14","author":"T Boonhaijaroen","year":"2024","unstructured":"Boonhaijaroen T, Choopong P, Tungsattayathitthan U, Tesavibul N, Sanphan W, Boonsopon S. Treatment outcomes in cytomegalovirus anterior uveitis. Sci Rep. 2024;14:15210.","journal-title":"Sci Rep"},{"key":"1250_CR42","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s10384-006-0383-4","volume":"51","author":"H Goto","year":"2007","unstructured":"Goto H, Mochizuki M, Yamaki K, Kotake S, Usui M, Ohno S. Epidemiological survey of intraocular inflammation in Japan. Jpn J Ophthalmol. 2007;51:41\u20134.","journal-title":"Jpn J Ophthalmol"},{"key":"1250_CR43","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1007\/s10384-012-0158-z","volume":"56","author":"N Ohguro","year":"2012","unstructured":"Ohguro N, Sonoda KH, Takeuchi M, Matsumura M, Mochizuki M. The 2009 prospective multi-center epidemiologic survey of uveitis in Japan. Jpn J Ophthalmol. 2012;56:432\u20135.","journal-title":"Jpn J Ophthalmol"},{"key":"1250_CR44","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1007\/s10384-020-00809-1","volume":"65","author":"KH Sonoda","year":"2021","unstructured":"Sonoda KH, Hasegawa E, Namba K, Okada AA, Ohguro N, Goto H, et al. Epidemiology of uveitis in Japan: a 2016 retrospective nationwide survey. Jpn J Ophthalmol. 2021;65:184\u201390.","journal-title":"Jpn J Ophthalmol"}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-025-01250-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10384-025-01250-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-025-01250-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T17:05:31Z","timestamp":1762880731000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10384-025-01250-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,9]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1250"],"URL":"https:\/\/doi.org\/10.1007\/s10384-025-01250-y","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,9]]},"assertion":[{"value":"14 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Y. Yoneda, None; Y. Takenaka, None; N. Taniguchi, None; K. Yoneda, None; K. Seki, None; T. Oyama, None; M. Imazeki, None; M. Takeuchi, None. The datasets used and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}